Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Clinical trial NCT00464646 · COMPLETED
Trial details
- NCT number
- NCT00464646
- Sponsor
- NSABP Foundation Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2009-12-01
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.